

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....
Fax Number:	Fax Number:	

Enoxaparin sodium

Initial application — Pregnancy, Malignancy or Haemodialysis

Applications from any relevant practitioner. Approvals valid for 1 year.

Prerequisites(tick boxes where appropriate)

<input type="checkbox"/> Low molecular weight heparin treatment is required during a patients pregnancy
or
<input type="checkbox"/> For the treatment of venous thromboembolism where the patient has a malignancy
or
<input type="checkbox"/> For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis

Initial application — Venous thromboembolism other than in pregnancy or malignancy

Applications from any relevant practitioner. Approvals valid for 1 month.

Prerequisites(tick boxes where appropriate)

<input type="checkbox"/> For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment
or
<input type="checkbox"/> For the prophylaxis and treatment of venous thromboembolism in high risk surgery
or
<input type="checkbox"/> To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery
or
<input type="checkbox"/> For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention
or
<input type="checkbox"/> To be used in association with cardioversion of atrial fibrillation

Initial application — Short-term use during treatment of COVID-19 with nirmatrelvir with ritonavir

Applications from any relevant practitioner. Approvals valid for 2 weeks.

Prerequisites(tick boxes where appropriate)

<input type="checkbox"/> Patient is receiving an anticoagulation treatment that has drug/drug interactions with ritonavir that increases risk of bleeding
and
<input type="checkbox"/> Patient meets the Access Criteria for COVID-19 antivirals published on the Pharmac website*
and
<input type="checkbox"/> Other antiviral treatments for COVID-19 have been considered and are not clinically suitable options

Renewal — Pregnancy, Malignancy or Haemodialysis

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 1 year.

Prerequisites(tick boxes where appropriate)

<input type="checkbox"/> Low molecular weight heparin treatment is required during a patient's pregnancy
or
<input type="checkbox"/> For the treatment of venous thromboembolism where the patient has a malignancy
or
<input type="checkbox"/> For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....
Fax Number:	Fax Number:	

Enoxaparin sodium - continued

Renewal — Venous thromboembolism other than in pregnancy or malignancy

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 1 month.

Prerequisites(tick box where appropriate)

Low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz